A phase II trial assessing the efficacy and tolerability of erlotinib + intensity modulated radiotherapy, in patients with liver or biliary cancer that is unresectable or refractory to treatment
Latest Information Update: 06 Nov 2007
At a glance
- Drugs Erlotinib (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- Sponsors OSI Pharmaceuticals
- 06 Nov 2007 New trial record.